Changeflow GovPing Healthcare & Life Sciences Anti-CD157 Antibodies, Fragments, Compositions,...
Routine Notice Added Final

Anti-CD157 Antibodies, Fragments, Compositions, and Methods

Email

Summary

The USPTO has published a patent application (US20260085128A1) detailing anti-CD157 antibodies, antigen-binding fragments, compositions, and methods for their use. The application was filed on July 18, 2023, and describes potential diagnostic reagents and kits.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

This document is a published patent application from the USPTO, specifically application US20260085128A1, titled 'Anti-CD157 antibodies, fragments, compositions, and methods described'. It details compositions and methods for making and using anti-CD157 antibodies or antigen-binding fragments thereof, including monoclonal antibodies, CD157-binding antibody fragments, and derivatives. It also covers nucleic acids encoding such molecules, diagnostic reagents, and kits.

As this is a patent application, it does not impose direct regulatory obligations or compliance deadlines on entities. However, it signifies potential future developments in therapeutic and diagnostic areas related to CD157. Companies operating in the pharmaceutical and biotechnology sectors should monitor this and related patent filings for insights into emerging technologies and potential intellectual property landscapes.

Archived snapshot

Mar 26, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

ANTI-CD157 ANTIBODIES, ANTIGEN-BINDING FRAGMENTS THEREOF AND COMPOSITIONS AND METHODS FOR MAKING AND USING THE SAME

Application US20260085128A1 Kind: A1 Mar 26, 2026

Inventors

Susannah Helene KASSMER-RODRIGUEZ, Weihao CHEN

Abstract

Compositions and methods for making and using anti-CD157 antibodies or antigen-binding fragments thereof, for example, monoclonal antibodies, CD157-binding antibody fragments, and derivatives are described, as are nucleic acids encoding such molecules, diagnostic reagents and kits that include anti-CD157 antibodies or antigen-binding fragments thereof, and methods of making and using the same.

CPC Classifications

C07K 16/2896 G01N 33/582 G01N 33/6854 C07K 2317/565 C07K 2317/75 C07K 2317/76 G01N 2333/70596

Filing Date

2023-07-18

Application No.

18992087

View original document →

Get daily alerts for USPTO Patent Applications - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260085128A1

Who this affects

Applies to
Drug manufacturers Medical device makers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing 3345 Medical Device Manufacturing
Activity scope
Drug Development Diagnostic Reagents
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Legal
Topics
Pharmaceuticals Intellectual Property

Get alerts for this source

We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!